A Prospective, Open Label Study of CERtican in KIdney Transplantation

Phase 4

Completed

• Conditions: Kidney Transplant
• Interventions: Drug: Everolimus

• Registration Number: NCT01594268
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

A prospective, open label study of CERtican in KIdney transplantation

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03
• Study First Submitted: 2012-05-04
• Study First Submitted QC: 2012-05-07
• Study First Posted: 2012-05-09
• Primary Completion: 2013-10
• Study Completion: 2013-10
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-17
• Last Update Posted: 2017-03-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Kidney transplantation patient	Everolimus	Kidney transplantation patient; single arm

Primary Outcome Measures

Name	Time	Method
Number of participants with serious adverse events	12 weeks	frequency of serious adverse event

Trial Locations

Locations (1)

Novartis Investigative Site; 🇰🇷 Suwon, Korea, Republic of